PMS2 and neoplasm: Previous tumor analysis in LLS17 showed an MSI-positive phenotype with loss of MLH1/PMS2 protein expression (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.140698DS1), WT BRAF V600E, and no MLH1 somatic hypermethylation.